abstract |
The present invention relates to compounds that bind to the cerebellum, a ubiquitously expressed E3 ligase protein (CRBN), and modify the substrate specificity of the E3 CRBN ubiquitin ligase complex, resulting in degradation of intrinsic downstream proteins. The compounds according to the invention are therefore useful for the treatment of various cancers. |